Please assess the completion status of the following clinical trial:

Trial Title: Identifying Factors That Predict Antidepressant Treatment Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Current DSM-IV diagnosis of major depressive episode, as determined by Structured Clinical Interview for DSM-IV (SCID-IV)~* Primary diagnosis of MDD, based on prominence of symptoms and target for intervention (comorbid anxiety disorders, except obsessive-compulsive disorder (OCD), will not be criteria for exclusion)~* Score of at least 18 on the 17-item Hamilton Rating Scale for Depression (HAM-D17)~* Agrees to use an effective form of contraception and/or double barrier method~Exclusion Criteria:~* Previously treated for major depression with either medication or psychotherapy~* Current psychosis, dementia, eating disorder, or dissociative disorder~* History of bipolar disorder (I and II) or schizophrenia~* Alcohol or drug dependence within 3 months prior to study entry or current alcohol or drug abuse (excluding nicotine and caffeine), as assessed by medical history and urine drug screening~* Requires neuroleptic or mood stabilizer therapy in addition to depression treatment~* Presence of any acute or chronic medical disorder that could affect successful completion of the trial~* Medical contraindications that would preclude treatment with escitalopram or duloxetine~* Presence of practical issues that would likely prevent completion of the study (e.g., planned geographical relocation)~* Pregnant or breastfeeding~* Medical conditions that could prevent the safe use of MRI (e.g., pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, or other implants; steel worker)~* Medical conditions that could prevent the safe completion of a dexamethasone-corticotropin releasing factor (Dex-CRF) test (e.g., uncontrolled hypertension, significant abnormalities in EKG, anemia, known allergies against drugs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: ACTIVE_COMPARATOR): Participants will receive treatment with escitalopram for 12 weeks
- Duloxetine (Type: ACTIVE_COMPARATOR): Participants will receive treatment with duloxetine for 12 weeks
- CBT (Type: ACTIVE_COMPARATOR): Participants will receive 16 one-hour sessions of cognitive behavioral therapy delivered over 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).